Tuesday, April 14, 2015

Barron’s Medical Journal Breast Cancer Person Of The Year “Jeanne Rizzo “ & A Cure Report


Barron’s Medical Journal ---- B.Bobby Graham Reporting : ---- From Rice University Houston, TX USA < GlobeNewswire>< PRWire> < PRNewswire>


Barron’s Medical Journal Breast Cancer Person Of The Year “Jeanne Rizzo “ & A Cure Report


Barron’s 10th Annual person of the year award for their contribution to breast cancer and A breast cancer cure is Jeanne Rizzo. Jeanne works for The Breast Cancer Fund and a breast cancer survivor.


Houston – ( AP ) -- Jeanne Rizzo’s vision guided the Breast Cancer Fund to adopt its bold mission to work to prevent breast cancer by eliminating our exposure to toxic chemicals and radiation linked to the disease. Under her direction the organization has become a national leader in translating the science linking breast cancer and environmental exposures into public education and advocacy campaigns that protect our health and reduce breast cancer risk.

Jeanne Rizzo President/CEO $ 173,580

Jeanne Rizzo’s vision guided the Breast Cancer Fund to adopt its bold mission of working to prevent breast cancer by eliminating exposure to toxic chemicals and radiation linked to the disease. Under her leadership the organization continues its commitment to strong science, smart public policy and consumer education. Ms. Rizzo co-chaired the National Institutes of Health’s Interagency Donald Pliner New Green Bottom Shoes Is The New Shoe Buzz Breast Cancer and Environmental Research Coordinating Committee, and is a recipient of the Environmental Protection Agency Region 9 Green Chemistry Environmental Leader Award. She is past chair of the California Breast Cancer Research Program Council and is a steering-committee member of the program’s Prevention Initiative. A nurse, then an award-winning music, theater and film producer, she produced the documentary Climb Against the Odds: Mt. McKinley, which chronicles the Breast Cancer Fund's 1998 expedition.

“when 1 in 8 women will be diagnosed with the disease, how much more awareness do we need? The Breast Cancer Fund is working to shift the conversation from awareness to prevention. We’re working to stop this disease before it starts, and we need the support of millions of people like you. You can start by pledging to go beyond the pink to prevention. “

In just a generation we’ve witnessed a 40-percent increase in breast cancer, and we know that environmental factors like toxic chemical exposures have played a major role. The Breast Cancer Fund is working to eliminate our exposure to toxic chemicals linked to the disease so that fewer of us, our daughters and increasingly our sons will ever have to hear the words, “You have breast cancer.”

Jeanne leads the organization’s strategic initiatives to remove the chemical bisphenol A, or BPA, from food packaging; to ensure cosmetics are non-toxic; and to overhaul the broken chemicals-management system that allows tens of thousands of toxic and untested chemicals to be used in consumer products. Recent legislative victories include the passage of a federal law banning toxic chemicals linked to breast cancer from toys, and California laws creating the first statewide biomonitoring program, advancing the safety of cosmetics and regulating chemicals in consumer products. Recent victories in the marketplace include a commitment from Campbell’s to remove BPA from its can linings and from Johnson & Johnson to globally reformulate its cosmetics products to remove harmful chemicals.

Breast Cancer Report Card Is A ( A ) ----- organizations like The Cancer Genome Atlas has made major advances in breast cancer research. Started in 2006 as a US $100-million pilot, The Cancer Genome Atlas (TCGA) is now the biggest component of the International Cancer Genome Consortium, a collaboration of scientists from 16 nations that has discovered nearly 10 million cancer-related mutations.

One of the best Research results is The Cancer Genome Atlas has identified four primary subtypes of breast cancer. Analyses of genomic data have confirmed that there are four primary subtypes of breast cancer, each with its own biology and survival outlooks. These TCGA findings are based on a large number of breast cancer specimens that capture a complete view of the genomic alterations. The four groups are called intrinsic subtypes of breast cancer: HER2-enriched (HER2E), Luminal A (LumA), Luminal B (LumB) and Basal-like. A fifth type, called Normal-like, was observed, but because of small numbers (only eight specimens) the researchers were unable to rigorously study it.

According to the World Health Organization, there are approximately 1.3 million new cases of breast cancer and 450,000 deaths worldwide annually. Breast cancer is the most common cancer among women. The majority of cases are sporadic, meaning there is not a family history of breast cancer, as opposed to genetic, where genes predispose a person to the disease.

Genomic Science has given the science community a opportunity to be optimistic about finding a cure. Our 1st Runner up for the person of the year is Dr. Staudt. Genomics is used in so many different ways for an example Dr. Staudt pioneered the use of gene expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy. He defined molecular subtypes of lymphoma that were previously unrecognized but are now viewed as distinct diseases that arise from different stages of B cell differentiation, utilize different oncogenic mechanisms and offer new therapeutic targets. To develop new treatments for lymphoid malignancies, Staudt’s laboratory uses various high-throughput approaches, including cancer gene resequencing, RNAi/CRISPR-based genetic screens, and combinatorial small molecule screens. The laboratory also conducts genomic investigations within therapeutic trials of targeted agents in lymphoma to define mechanisms of response and resistance.

Through The Cancer Genome Atlas (TCGA) (http://tcga.cancer.gov/), a joint effort of the National Cancer Institute and the National Human Genome Research Institute, we will greatly expand our understanding of the genetic basis of more than 20 cancers that affect adults and identify specific molecular changes that can be targeted for the development of new treatments or exploited to detect cancer earlier or prevent its occurrence.

The Top Rated Cancer Funds if you are looking for a tax deduction here is a list of Award winning organization to donate to says Barron’s Medical Journal

Breast Cancer Fund A-

Breast Cancer Research Foundation A+

Cancer Research Institute A Entertainment Industry Foundation A-

Leukemia and Lymphoma Society B+

LiveStrong Foundation A-

Memorial Sloan-Kettering Cancer Center A

Movember Foundation A

Multiple Myeloma Research Foundation A

National Breast Cancer Coalition Fund A

Ovarian Cancer Research Fund A Prevent Cancer Foundation B+

Prostate Cancer Foundation A

Friday, March 20, 2015

Can A Breast Cancer Cure Be Stopped -- By Supreme Court Justice Clarence Thomas:


Barron’s Medical Journal B.Bobby Graham reporting From The University Of Texas Austin -- Austin, TX USA Can A Breast Cancer Cure Be Stopped -- By Supreme Court Justice Clarence Thomas:

Austin ----( AP ) Genomic Science has cleared the run way for a breast cancer cure. Barron’s Medical Journal is in Austin, Texas to report on the re- installation of the Cancer Prevention and Research Institute of Texas (CPRIT). Breast cancer scientist is using genomic science to find a cure more and more. This is great news for Texas scientist. Texas is one of the States in The United States to supply research grants to find cures for cancer. 89 % of cancer researchers interviewed say having more breast cancer patients going to the Doctor more often and being diagnosed early-- Donald Pliner New Green Bottom Shoes Is The New Shoe Buzz is a great help. With the Affordable Care Act (ACA or Obamacare) in place scientist can use genomic science to come up with a cure. Even the Microsoft Corporation has joined the race for a cure by using their Cloud Computing service to help scientist and Doctors to analyze breast cancer genome information.

Cancer Prevention and Research Institute of Texas (CPRIT) -- Texas voters overwhelmingly approved a constitutional amendment in 2007 establishing the Cancer Prevention and Research Institute of Texas (CPRIT) and authorizing the state to issue $3 billion in bonds to fund groundbreaking cancer research and prevention programs and services in Texas. CPRIT’s goal is to expedite innovation in cancer research and product development, and to enhance access to evidence-based prevention programs throughout the state. Under the guidance of its governing body, the Oversight Committee, CPRIT accepts applications and awards grants for a wide variety of cancer-related research and for the delivery of cancer prevention programs and services by public and private entities located in Texas. All CPRIT-funded research will be conducted in state by Texas-based scientists and reflect CPRIT’s mission to attract and expand the state’s research capabilities and create high quality new jobs in Texas.

CPRIT will maintain the highest integrity and dedication to the mission of finding a cure for cancer. CPRIT’s objective is to position Texas as a world-class leader in research and prevention through collaboration with a variety of entities, including public and private institutions of higher education, academic health institutions, universities, governmental organizations, nongovernmental organizations, public and private companies and others involved in the fight against cancer. CPRIT supports innovation in the selection of research projects emphasizing immediate or long-term medical breakthroughs; product development opportunities for research, and prevention services and health education for citizens with culturally appropriate information about ways in which their risks of developing and dying from cancer can be reduced.

Who is Clarence Thomas. Clarence Thomas was born on June 23, 1948, in Pin Point, Georgia. He served in the administrations of Reagan and George H.W. Bush. After the retirement of African-American Supreme Court Justice Thurgood Marshall led George H.W. Bush to nominate Thomas as his replacement and he was narrowly confirmed in 1991. Thomas is a conservative.

Barron’s Medical Journal has learned with Justice Thomas vote the Supreme court may overturn President Obama care. How can this happen? The matter before the court is King v. Burwell. If the plaintiffs in King v. Burwell are successful, an Obama Administration rule granting certain premium tax credits to those who obtain insurance through federal health care “exchanges” will be struck down. Absent action by the federal government or states, a ruling for the plaintiffs and against the Obama Administration would mean that individuals for whom insurance coverage became a greater out-of-pocket expense (exceeding 8 percent of their income in any given month) without the premium support tax credit would become exempt from the individual mandate. Furthermore, employers in states that refused to set up Obamacare exchanges would be exempt from the employer mandate because no federal outlays would be made to trigger the penalty. King is a consequential initial step on the road toward dismantling and replacing the ill-considered Obamacare statutory scheme. On March 4, the Supreme Court of the United States heard oral argument in King v. Burwell. This case is a challenge by individuals (petitioners) who do not wish to comply with the so-called minimum coverage provision of the Patient Protection and Affordable Care Act (ACA or Obamacare).

Millions of individuals in the 34 states served by the FFMs will lose their tax credits. Without the credits, they will no longer be able to afford health insurance. The cost of insurance to those remaining in the nongroup market will rise precipitously, causing even more Americans to lose coverage. As the number of uninsured increases, providers will bear an increased burden of uncompensated care. A decision for the plaintiffs, that is, will be disaster for the American health care system.

The challengers argue that this is a result Congress intended. They contend that the subsection of the Affordable Care Act dealing with the calculation of premium tax credits limits the credits to individuals enrolled in an “Exchange established by the State.”-- True & Real By Theresa Roemer The government argues that this is a term of art — that Congress intended this phrase to include the federally facilitated exchanges that the ACA requires the Department of Health and Human Services to create as a fallback where the states elect not to operate their own exchange. Dozens of other provisions of the ACA support the government’s position.

The federal district court in Virginia that originally heard the case ruled for the government, holding that the statute unambiguously supported the IRS rule. The Fourth Circuit Court of Appeals affirmed unanimously. The Fourth Circuit held that, although the government had the better argument, the statute was ambiguous; thus the IRS regulation should be upheld under the Chevron Rule, which requires courts to defer to administrative agency interpretations of statutory ambiguities. Judge Davis, concurring, concluded the statute clearly supported the IRS. In a highly unusual move, the Supreme Court took review of the case in the absence of a split between the circuits.

The argument was supposed to last an hour, but in fact went on for almost an hour and a half. It is a masterpiece—two highly competent counsel thoroughly in control of their arguments being grilled by Justices who had obviously read the briefs, thought about the issues, and prepared themselves to ask probing and difficult questions.

Although the question of standing came up again when Solicitor General Verrilli took the podium and one more time when Carvin returned for rebuttal, no one seemed eager to have the case decided on this basis at this point and everyone seemed ready to move on.

The meaning of exchange in the ACA. Justice Breyer did move on to press Carvin, repeating the key argument of the government that “exchange” is a defined term under the ACA. It is defined as a 1311 exchange, which in turn is defined as an exchange “established by a state.” Section 1321 requires HHS to set up “such exchange,” that is a “required” 1311 state exchange when a state elects not to do so. Having recited this argument, Breyer asked: “So what’s the problem?” Carvin responded, as he has all along, that the statute does not say an “exchange established under 1311,” but rather, an “Exchange established by the State under 1311.”

In response Justice Kagan posed a hypothetical. If she asked one of her clerks to write a memo, another to edit it, and a third to write it if the first was too busy, and the third in fact wrote it, should the second still edit it? Mr. Carvin, seeing where this was going (and aided by Justice Alito) protested the analogy because Congress in fact was not indifferent as to which clerk wrote the memo, that is, who set up the exchange. But, Justice Kagan responded, the only way we know whether Congress was indifferent is from the context of the four or five words on which the plaintiffs build their case, just as the context would determine the meaning of the instructions to the clerks.

Justice Breyer pressed on. Literally, under the statute the federal government establishes an exchange for the state, which the statute defines as an exchange established by the state. But even if you don’t read the statute literally, federal exchanges make no sense without tax credits.

Carvin pointed out that the ACA more literally defines territorial exchanges as equivalent to state exchanges, but the justices were not persuaded of the distinction. Interpreting the ACA to avoid unconstitutional coercion. And here they reached what may well prove to be the turning point of the argument. Justice Sotomayor pointed out that if the plaintiffs’ argument is right, states that elect not to operate their own exchanges face tremendous penalties. Not only do their residents lose the tax credits, but their nongroup insurance markets will collapse and they will be blocked from reducing Medicaid eligibility (and states that already have may lose Medicaid funding altogether). This is clearly, Sotomayor argued, unconstitutionally coercive under recent Supreme Court cases.

To predict the result of a case from oral argument, it seems the government came out of the argument on top. The government’s position is clearly supported by Justices Breyer, Kagan, Ginsburg, and Sotomayor. It seems to me that the government has a more than even shot at Justice Kennedy. It is clear that Justices Scalia and Alito are prepared to side with the challengers. The Chief Justice, however, did not clearly stake out a position one way or the other. Justice Thomas, as is his custom, was silent, although the government should probably draw no comfort from that. At this point it would change the legacy of Justice Thomas if he see this matter constitutional vitality and a breast cancer cure.

Tuesday, February 24, 2015

How Can Some People Smoke All Of Their Adult life And Not Get Lung or Breast Cancer:

Barron’s Medical Journal Reporting From MD Anderson Cancer Center Woodland, Texas USA B. Bobby Graham Reporting:

How Can Some People Smoke All Of Their Adult life And Not Get Lung or Breast Cancer:


Woodland, TX ( AP ) News ----- How can some people smoke all of their adult life and not get lung or breast cancer and others people and their families’ will get lung cancer. Spleen tyrosine kinase (SYK) researcher’s has given Scientist around the world new information and a major step to a cure. With the advent of genomic science, scientist has added to the P53 gene --- SYK gene.

Spleen tyrosine kinase (SYK) is a non-receptor type cytoplasmic protein and a known tumor suppressor gene in breast and lung cancer. When a copy of your SYK gene is lost, 51 other genes are directly affected. This leads to genetic disruption. A tumor suppressor gene, or antioncogene, is a gene that protects a cell from one step on the path to cancer. When this gene mutates to cause a loss or reduction in its function, the cell can progress to lung and breast cancer.


Researcher has discovered patients with lung adenocarcinomas diagnosed each year in the United States have tumors that carry a mutation called V600E BRAF. The BRAF gene makes a protein that affects how cancer cells divide and grows. The powerful tumor suppressor gene, SYK, as well as genetic alterations in 51 other genes that are directly affected by the loss of a copy of the SYK gene and the absence of its protein is a major cause of breast cancer. Genomic science is gaining popularity and many Doctors throughout the United States and around the world. Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). With so many folks getting diagnosed with lung cancer, personalized medicine core foundation uses genes. Our genes are the molecular unit of heredity of a living organism. It is used extensively by the scientific community as a name given to some stretches of deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) that code for apolypeptide or for an RNA chain that has a function in the organism.

Proteins are large biological molecules, or macromolecules, consisting of one or more long chains of amino acid residues. The key elements of an amino acid are carbon, hydrogen, oxygen, and nitrogen, though other elements are found in the side-chains of certain amino acids. About 500 amino acids are known and can be classified in many ways. Lung cancer is the leading cause of cancer-related deaths among men and women. According to the National Cancer Institute, an estimated 224,210 Americans will be diagnosed with lung cancer, and 159,260 will die from the disease this year. About 85 percent of lung cancers are NSCLC, making it the most common type of lung cancer. However, only 2-7 percent of patients with NSCLC are ALK-positive.

How we use to treated lung Cancer in 1975, the incidence rate for all cancers combined in the United States was 400 new cases for every 100,000 people in the population; the mortality rate was 199 deaths for every 100,000 persons. Among adults diagnosed with cancer during the period from 1974 through 1976, the 5-year relative survival rate for all cancers combined was 50%. Among whites, it was 51%; among blacks, it was approximately 40%. During the same period, the 5-year relative survival rate for all childhood cancers combined was about 62%. (Note: Relative survival compares the survival of a cancer patient to that of an average person of the same age and sex.) For the five most common cancers diagnosed in adults, the 5-year survival rates were: breast, 75%; prostate, 69%; lung, 13%; colorectal, 51%; and bladder, 74%.

In the mid-1970s, approximately 37% of U.S. adults were current smokers. In 1975, the lung cancer mortality rate among men was about 76 deaths per 100,000 persons; among women, it was about 18 deaths per 100,000 persons. In the mid-1960s, clinical investigation of combination chemotherapy, using multiple drugs with different mechanisms of action, in the treatment of cancer was just beginning. Clinical studies of anticancer vaccines (treatment or prevention) had not yet begun.

Through The Cancer Genome Atlas (TCGA) (http://tcga.cancer.gov/), a joint effort of the National Cancer Institute and the National Human Genome Research Institute, we will greatly expand our understanding of the genetic basis of more than 20 cancers that affect adults and identify specific molecular changes that can be targeted for the development of new treatments or exploited to detect cancer earlier or prevent its occurrence. If you have lung, the great news is Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011. Dabrafenib a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. In 2014 Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

Discovery of key genes and proteins that spark and fuel lung cancers (ie, driver genes) has shifted the focus of lung cancer treatment toward targeted therapies. This year, strategies of screening for genetic changes in lung tumors and matching patients to appropriate targeted treatments were reported, thus delivering on the promise of personalized medicine. Early results showed encouraging antitumor effects of dabrafenib against BRAF-positive lung cancers and LDK378 and AF802 for ALK-positive lung cancers.

A total of 1,007 patients with metastatic adenocarcinomas (the most common subtype of NSCLC) were tested for at least one genomic mutation, and 733 underwent testing for all 10 known lung cancer oncogenic drivers: KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, NRAS, ALK, and MET. A driver was detected in 622 (62%) of 1,007 patients with at least one gene tested, and 465 (63%) of 733 patients who underwent testing for all 10 genes. Mutations in KRAS, EGFR, and ALK genes accounted for approximately half of all driver mutations detected. Twenty-nine patients (4%) had mutations in two driver genes.

These findings were then used to select available targeted therapies or appropriate clinical trials testing new targeted therapies in 279 patients with a driver mutation. Clinical follow-up and treatment information was assessed for 938 patients. Among the 622 patients with a driver mutation detected, those treated with targeted therapy (264 patients) had a median survival of 3.5 years, and those who did not have a targeted therapy available (313 patients) had a median survival of 2.4 years. The 361 patients without identified driver mutations had a median survival of 2.1 years. This study demonstrates that close to two thirds of all patients with lung adenocarcinomas harbor mutations in known lung cancer driver genes and that matching patients with treatments targeted specifically to those drivers leads to improvements in survival.

Nearly 3,000 patients with lung adenocarcinomas diagnosed each year in the United States have tumors that carry a mutation called V600E BRAF. The BRAF gene makes a protein that affects how cancer cells divide and grow. An oral drug that blocks the BRAF protein, dabrafenib, has recently shown dramatic effects in patients with BRAF V600E– positive metastatic melanoma.

Saturday, January 24, 2015

President Obama Community College Concept Can Work By Offering A Genomics And Bioinformatic Technology Major

Barron’s Medical Journal And B. Bobby Graham ---Reporting From Washington, DC USA ---At The Phacilitate's Washington 11th Annual Cell & Gene Therapy Forum Stem Cells as Discovery and Research Tools Forum

President Obama Community College Concept Can Work By Offering A Genomics and Bioinformatic Technology Major:


Washington DC ( AP) ----- President Obama is on to something Congress Women Shelia Jackson Lee, Congressman Al Green, Texas Governor Gregg Abbott, Houston Mayor Annise Parker and Houston Community College System. If HCC located in Houston Texas will offered a Genomics and Bioinformatic technical major, this innovative idea will create several thousand jobs and the Free Community College program will pay for itself. President Obama Community College Free For Millions Of Students. On January 9, Obama announced a plan to make community college free for "all students if they attend classes at least half time and maintain a grade point average of 2.5 or better,"

Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism).

President Obama Community College Concept Can Work By Offering A Genomics and Bioinformatic Technical Major Bioinformatic is the science of computer information systems. As an academic field it involves the practice of information processing, and the engineering of information systems.

Laura Rathe Fine Art

Barron's Medical Journal Interview London England's Angel Biotechnology

The Genomics and Bioinformatic course should cover gene privacy administration; Gene data disseminate, management, and interpret of large, multi-scale cloud data.

Lets discuss the need for privacy, Female patients with breast cancer (n=100) completed a questionnaire assessing attitudes regarding concerns about privacy of genomic data.

Laboratory: Sunnyvale Center: Palo Alto Scientist Interview On Genomic & Infomatics

Results Most patients (83%) indicated that genomic data should be protected. However, only 13% had significant concerns regarding privacy of such data. Patients expressed more concern about insurance discrimination than employment discrimination (43% vs 28%, p<0.001). They expressed less concern about research institutions protecting the security of their molecular data than government agencies or drug companies (20% vs 38% vs 44%; p<0.001). Most did not express concern regarding the association of their genomic data with their name and personal identity (49% concerned), billing and insurance information (44% concerned), or clinical data (27% concerned). Significantly fewer patients were concerned about the association with clinical data than other data types (p<0.001). In the absence of direct benefit, patients were more willing to consent to sharing of deidentified than identified data with researchers not involved in their care (76% vs 60%; p<0.001). Most (85%) patients were willing to consent to DNA banking. Discussion While patients are opposed to indiscriminate release of genomic data, privacy does not appear to be their primary concern. Furthermore, we did not find any specific predictors of privacy concerns.

Conclusions Patients generally expressed low levels of concern regarding privacy of genomic data, and many expressed willingness to consent to sharing their genomic data with researchers.

Cancer therapy is increasingly personalized to the molecular characteristics of a particular patient and his/her tumor.1 The National Cancer Institute (NCI) defines personalized cancer therapy as the ‘application of genomic and molecular data to tailor medical care to individuals’.

2 Personalized cancer therapy has the potential to improve treatment response, reduce adverse effects, and reduce cost of care.3 In this paper, we refer to personalized, precision and genomically informed cancer therapy interchangeably. Similarly, although the terms ‘genetic’ and ‘genomic’ have distinct scientific meanings,3a we favored the more familiar ‘genetic’ in the questionnaire administered to patients and were not strict about the distinction.

Although patients and providers express an interest in genomically informed therapy,4 concerns regarding the privacy of genomic data have been raised, particularly in the context of research.5 6 Genomic data cannot be completely ‘deidenti- fied’, 7 8 thus these data pose a serious privacy risk. As a result, the storage and sharing of genomic data in the context of research is presently a topic of much debate.9

Data from a Gallup poll10 showed that medical privacy is important to people in the general population, and privacy concerns related to genetic testing and hereditary cancers have been raised.11 However, previous studies have asked general questions about medical privacy, such as ‘Who do you think should be allowed to see your medical records without your permission?’. 10 Such questions are not representative of current research being considered or conducted where identified data are collected for specific, explicitly defined purposes. Furthermore, many studies have focused almost exclusively on healthy participants, who did not have an established relationship with a research organization where they were receiving care. Thus, previous studies may not have considered the specific privacy concerns of patients with cancer, for whom molecular testing and genetic research may have direct and indirect benefits.

Finally, little is known about patients’ privacy concerns related to molecular testing in personalized cancer therapy, which mainly focuses on information related to somatic (as opposed to germline) mutations.12 In contrast with germline mutations, somatic mutations are not heritable. Thus, from a privacy perspective, they may be less concerning to patients.

Understanding patients’ privacy concerns regarding genomic data may help researchers and clinicians better address patient concerns, and may encourage participation in genomic studies.13 Further, patients rather than the general public are the most relevant population. Our results may also help to align the public policy debate with the concerns of patients, rather than the general public.

Cloud Data and The challenges posed by the need to disseminate, manage, and interpret large, multi-scale data pervade efforts to advance understanding of cancer biology and apply that knowledge in the clinic. For several years, the volume of data routinely generated by high-throughput research technologies has grown exponentially. The storage, transmission, and analysis of these data have become too costly for individual laboratories and most small to medium research organizations to support. For optimal progress to occur, access to large, valuable data collections and advanced computational capacity must be readily available to the widest possible audience.

“ On April 7, 2013, Dr. Harold Varmus and other members of the Institute's senior leadership issued a letter to NCI grantees seeking input on these and other computational challenges they encounter on an almost daily basis. Dr. Varmus stated that the NCI, as part of its ongoing investigations into next-generation computational capabilities to serve the research community, has begun exploring the possibility of creating one or more public "cancer knowledge clouds" in which data repositories would be co-located with advanced computing resources, thereby enabling researchers to bring their analytical tools and methods to the data. Reactions to this informal request for information were generally positive, with respondents focusing on six general themes: data access; computing capacity and infrastructure; data interoperability; training; usability; and governance.”

Based in part on this information, Dr. George Komatsoulis, then interim director of the Center for Biomedical Bioinformatic and Information Technology (CBIIT), which administers the National Cancer Informatics Program (NCIP), led the creation of a concept document describing a project to develop up to three cancer genomics cloud pilots for review by the cancer-research community. Dr. Komatsoulispresented the concept (time reference 05:58:00) at a joint meeting of the NCI Board of Scientific Advisors (BSA) and the National Cancer Advisory Board (NCAB) on June 24, 2013, where it received unanimous approval.

One great example of the type Bioinformatic technology is the Very Gene project. VeryGene is developed as a curated, web-accessible centralized database for the annotation of tissue-specific/enriched genes. It currently contains entries for 3960 human genes covering 128 normal tissue/cell types compiled from the expression profiling of two large microarray data sets [ref1, ref2]. It brings together much-needed information on preferred tissue/subcellular localization, functional annotation, pathway, mammalian phenotype, related diseases and targeting drug associated with any of these genes as a result of data integration from multiple sources. Information can be searched through gene, tissue and disease views and search result can be downloaded easily. We commit our best efforts to update and expand VeryGene as new and relevant information emerges

As an initiative toward systems biology, the VeryGene web server was developed to fill this gap. A significant effort has been made to integrate TSGs from two large-scale data analyses with respective information on subcellular localization, Gene Ontology, Reactome, KEGG pathway, Mouse Genome Informatics (MGI) Mammalian Phenotype, disease association, and targeting drugs. The current release carefully selected 3,960 annotated TSGs derived from 127 normal human tissues and cell types, including 5,672 gene-disease and 2,171 drug-target relationships. In addition to being a specialized source for TSGs, VeryGene can be used as a discovery tool by generating novel inferences. Some inherently useful but hidden relations among genes, diseases, drugs, and other important aspects can be inferred to form testable hypotheses.

Two interactive matrix views have been developed to provide users with intuitive, high-level summaries of expression data and from where they can easily move to levels of greater detail. The tissue-by-developmental stage matrix provides global overviews of the spatio-temporal expression patterns of genes. The tissue-by-gene matrix enables a comparison of expression patterns between genes. Both types of matrices can be expanded (and collapsed) along the tissue axis, based on the hierarchical organization of the anatomy. Rows and columns in the matrices can be selected to refine the data set. The matrices have been added as new tabs to the gene expression data summaries. These matrices can be accessed by searches using the Gene Expression Data Query and via links from the Mouse Developmental Anatomy Browser.

The Gene Expression Data Matrix is now accessible from the Access Data section of http://www.informatics.jax.org/expression.shtml It returns all of GXD's expression data in a tissue-by-developmental stage matrix. When using this matrix, users start with a high-level overview of GXD's data and then can interactively view and select expression data for the specific tissues and / or developmental stages of interest.

The standard Gene Expression Data Query now lets users define gene sets based on genomic location. One can, for example, search for disease candidate genes that have been mapped to a genomic region and are expressed in tissues affected by the disease.

Texas can be the leader Barron’s Medical Journal.

Saturday, January 10, 2015

State Of The Union For Breast Cancer

Barron’s Medial Journal and B.Bobby Graham reporting from Southern Methodist University (SMU) Southwestern's medical school in Dallas, Texas USA


State Of The Union For Breast Cancer:

Edited in Houston, Texas by Trenette Allen


Dallas ( AP ) ---- A women getting married in 2015 under the age of 40 has an 85% chance of surviving due to a breast cancer diagnosis. Genomics and Informatics is on the goal line. Barron’s Medical Journal says a cure may happen before the end of President Obama's second term.

Informatics is the science of information. As an academic field, it involves the practice of information processing, and the engineering of information systems. It studies the structure, algorithms, behavior, and interactions of natural and artificial systems which store, process, access, and communicate information.

We spoke with the Chief Information Officer of the informatics technology company Gen-Tek Inc. and what we found was a demand in the clinical trial setting and research center across the United States is at an all- time high. In fact, an Informatics engineer has a 97% chance of having a job offer before they graduate.

Breast cancer research two major developments: targeted treatments (small molecule inhibitors and monoclonal antibodies) and massive parallel sequencing of tumor genomes, also known as next-generation sequencing (NGS). By using these platforms, a great deal of information can be obtained in a very short time.

Cancer cells are dependent on oncogenic expression to maintain malignancy, and these can be used as predictive biomarkers. Examples include the following: oncogene addiction as in HER2 amplification in breast cancer, the KIT mutation in gastrointestinal stromal tumors, epidermal growth factor receptor mutations and/or amplification in nonsmall cell lung cancer, and the BRAF V600E mutation in melanoma. Data obtained from sequencing tumors from patients with breast cancer has revealed a high level of intertumor and intratumor heterogeneity, with very few highly recurrent mutations. It has also become apparent that not every tumor has an identifiable driver mutation, and not all drivers of metastatic disease or resistance have been identified. “It is only by harnessing the knowledge from intra- and intertumor heterogeneity that we will be able to realize the application of precision medicine.

The truth of the matter is, we treat cancer today, we guess. We take what we call the average results, put it in, and see if it works. If it doesn't work, oops, we'll try another drug. If it does work, we stop the drug. When you look back 10 years from now, it's almost barbaric.

Dr. Soon-Shiong 62-year-old native of South Africa can afford to be outspoken because of his immense wealth. He doesn't need to rely on the government or Big Pharma for funding. Soon-Shiong is certain that what he terms "the Dark Age of cancer treatment" is nearly over, and "the Enlightened Age" is about to begin.

The treatment doesn't need to be painful. Metastasis doesn't need to be a death sentence. Cancer could be a chronic disease...and treated towards the cure.

While the oncology world may cringe when he boasts, as he's prone to do, patients see him differently. He believes chemotherapy works best when administered in frequent, low doses and that in some cancers the traditional method of blasting a tumor with heavy doses of chemotherapy may actually be counterproductive - because it could induce cancer cells to escape the hostile environment, enter the bloodstream and find a new home. Soon-Shiong has teamed with Blackberry to produce a device that will identify for patients and doctors what they need to make more informed decisions.

Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). We then ask Rose is her company doing any work with Genomics for breast cancer and if so explain the process. Genomics is the Gaussian processes in action, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Sam Houston to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Sam Houston has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Sam Houston for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. Breast cancer researchers and scientists are ahead of the curve with several new technologies based on nanoparticles and semi conductors namely genomics and treatments. The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.

The result is that the ability to determine targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data. The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3,000.00. The lower cost, along with increasing speed, has led to a huge increase in how much breast cancer sequencing data is being produced.

Numerous investigations have shown that both tissue and cell distribution profiles of anti-cancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The invivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also a benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells.

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid Sam Houston researchers say that nanotechnology will allow them to run many diagnostic tests simultaneously. Nanoparticles nanoshells is use to antibodies that recognize cancer cells. Sam Houston scientists envision letting these nanoshells seek out their cancerous targets, then apply near-infrared light. The heat generated by the light-absorbing nanoshells can successfully kill breast cancer tumor cells while leaving neighboring cells intact.

Thursday, December 4, 2014

Neuroplasticity Can Improve Quality Of Life For Seniors

Barron’s Medical Journal Reporting from Texas Medical Center M.D. Anderson Research Center Houston, Texas USA B. Bobby Graham Reporting

Neuroplasticity Can Improve Quality Of Life For Seniors


Houston ( AP ) Neuroplasticity explains why people who knew me as a elementary student and my ability to learn is so much different as in today, where in many circles when people meet me it is clear to them they are speaking to one of superior abilities.

Neuroplasticity demonstrate that the adult brain can continue to form novel neural connections and grow new neurons in response to learning or training even into old age. Brought To You By Dream So Big Book

Neuroplasticity, also known as brain plasticity, is an umbrella term that encompasses both synaptic plasticity and non-synaptic plasticity—it refers to changes in neural pathways and synapses due to changes in behavior, environment, neural processes, thinking, emotions, as well as changes resulting from bodily injury.

The human brain is a complex, self-organizing, biological system, consisting of trillions of interconnected nerve cells called neurons. The operation of neurons results in two distinct forms of information processing: signaling and integration. Each neuron propagates signals Brought To You By JulieBeth HandBags via action potentials, electrochemical currents that travel the length of its axon. This current leads to the release of neurotransmitters which traverse synapses, the gaps between neurons. These chemical messages are received via specialized receptor cells at the ends of numerous, tree-like branches of the receiving neuron, called dendrites. The stimulation of dendritic receptors by neurotransmitters leads to integration, whereby large amounts of information from many neurons is summed up before reaching a threshold to fire the action potential JulieBeth HandBags down the next axon. In this manner, perceptual information from the external environment and the internal milieu of the body is transmitted and processed in the brain, leading to cognition, emotion, and behavior, the essence of human experience.

Brought To You By 2014 Cadillac ELR

The notion that social experience can lead to changes in gene expression was voiced most prominently by Nobel laureate, Eric Kandel, who regarded this observation as the core component of a new paradigm for psychiatry (1998). Kandel summarized the current state of biological thinking with regard to the relation between social experiences and neurobiology, observing that:

The regulation of gene expression by social factors makes all bodily functions, including all functions of the brain, susceptible to social influences. These social influences will be biologically incorporated in the altered expressions of specific genes in specific nerve cells of specific regions of the brain. These socially influenced alterations are transmitted culturally

The brains of infants and children are known to be plastic, undergoing spurts of neuronal development in response to stimulus exposure during critical periods. This development consists of the genesis of neurons, increased connectivity between extant neurons, and the routing of new synaptic connections between previously unrelated neurons. For instance, violinists evidence neural growth in the portion of their somatosensory cortex devoted to their fingering hand through hours of musical practice.

Persons suffering from what was once thought to be permanent brain injury can heal through rehabilitation designed to stimulate the damaged area, such as in the case of stroke However, although largely speculative, it is possible that neuroplasticity may undergird not only rehabilitation of physical illness but that of select psychological disorders as well, mediating natural recovery from mental illness in some cases as well as improvements related to psychosocial interventions. At present, it has been demonstrated that psychotherapy can induce functional changes in brain activation.

The DNA code of the human genome does not determine protein synthesis in a one-toone fashion; instead, genes are subject to epigenetic processes (i.e. modifications that do not occur due to changes in the basic genetic sequence of amino acids but that instead result from biological and environmental influences on the expression of genes as proteins During gene expression, the genetic code serves as a “blueprint” that guides the construction of proteins from amino acids. However, this construction process is modulated by signals from the internal and external environments, which steer and modify the manner in which basic organic molecules are organized into anatomy and physiology. 1. In neuroscience, synaptic plasticity is the ability of synapses to strengthen or weaken over time, in response to increases or decreases in their activity. Plastic change also results from the alteration of the number of neurotransmitter receptors located on asynapse.

Nerve cells communicate by using chemical messengers, which are released from neurons after a “priming” step. It seems that priming may be the key to controlling the strength of chemical transmission. The roots of cognition, behavior, learning and memory are embedded in the brain’s intricate network of nerve cells and their specialized points of contact, the synapses. Synapses can convert electrical impulses into chemical signals and back again, as well as modulate the strength of the transmitted signals. This ability to modify the strength of transmission—known as synaptic plasticity—is thought to be the cellular basis of the brains ability to compute, learn and remember. A goal of many neurobiologists is to understand the molecular basis of synaptic plasticity

Neuroinformatics stands at the intersection of neuroscience and information science. Other fields, like genomics, have demonstrated the effectiveness of freely-distributed databases and the application of theoretical and computational models for solving complex problems. In Neuroinformatics, such facilities allow researchers to more easily quantitatively confirm their working theories by computational modeling. Additionally, neuroinformatics fosters collaborative research—an important fact that facilitates the field's interest in studying the multi-level complexity of the brain.

Brought To You By Theresa Roemer True and Real collection

There are three main directions where neuroinformatics has to be applied:[2] 1. the development of tools and databases for management and sharing of neuroscience data at all levels of analysis,

2. the development of tools for analyzing and modeling neuroscience data,

3. the development of computational models of the nervous system and neural processes.